Clinical Trial Update: Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNA [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating olmutinib in T790M-positive non-small cell lung cancer detected via liquid biopsy in BALF extracellular vesicular DNA has comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Olmutinib (olmutinib)

Snippet

Sponsor: Konkuk University Medical Center | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: COMPLETED